EPCAM and hepatocellular carcinoma: Treatment with PPARγ-specific antagonists or SCD1 inhibitors effectively decreased the sphere-forming capacity of HCC Huh7 and Hep3B cells, resulting in the loss of CSC properties through reduced expression of CSC-related markers such as EpCAM, CD133, CD24, KRT19, and ICAM1 [68].